Osteoporosis in the practice of the physician-endocrinologist: modern methods of treatment


Cite item

Full Text

Abstract

Modern data on the nature of osteoporosis (OP) are presented. Forms of osteoporosis associated with endocrine diseases (thyroid pathology, diabetes mellitus, Cushing's basophilism, hyperparathyroidism) are considered. It is emphasized that the endocrinologist in the clinical practice uses the whole arsenal of medicines for treatment and prophylaxis of OP, such as both hormonal and nonhormonal methods for therapy of primary and secondary forms of OP. We discuss the modern methods of pathogenetic therapy and prophylaxis of OP using bisphosphonates, strontium ranelate, active metabolite of vitamin D, and several other drugs. Administration of these drugs can effectively prevent bone fractures in the OP.

References

  1. Белая Ж.Е., Мельниченко Г.А., Рожинская Л.Я и др. Минеральная плотность костной ткани и показатели костного метаболизма у женщин в менопаузе с субклиническим тиреотоксикозом различного генеза // Остеопороз и остеопатии. 2005. № 2. С. 14-18.
  2. Лесняк О.М., Беневоленская Л.И. Остеопороз. Диагностика, профилактика и лечение. Российская ассоциация по остеопорозу. Клинические рекомендации. Изд-во Геотар-Медиа. 2009. С. 3-269.
  3. Рожинская Л.Я., Дзеранова Л.К., Марова Е.И. и др. Применение кальция и витамина D для профилактики остеопороза у женщин в постменопаузе // Остеопороз и остеопатии. 2001. № 1. С. 29-33.
  4. Abe E, Marians RC, et al. TSH is a negative regulator of skeletal remodeling. J Cell 2003;115:151-62.
  5. Ammann P, Badoud I, Barraud S, et al. Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength. J Bone Mineral Res 2007;22:1419-25.
  6. Blake GM, Fogelman I. Theoretical model for the interpretation of BMD scans in patients stopping strontium ranelate treatment. J Bone Mineral Res 2006;21:1417-24.
  7. Blake GM, Compston JE, Fogelman I. Could strontium ranelate have a synergistic role in the treatment of osteoporosis? J Bone Mineral Res 2009;24:1354-57.
  8. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. FIT Research Group. Lancet 1996;348:1535-54.
  9. Black DM, Delmas PD, Eastell R, et.al. Once-yearly zolendronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
  10. Boivin G, Farley D, Simi C, Meunier PJ. Bone strontium distribution and degree of mineralization of bone in postmenopausal osteoporotic women treated with strontium ranelate for 2 and 3 years. Osteoporos Int 2006;17(suppl. 2):s210.
  11. Bruyere O, Roux C, Detilleux J, et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 2007;92:3076-81.
  12. Cauley JA, Robbins J, Chen Z, et.al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. WHI randomized trial. JAMA 2003;290:1729-38.
  13. Chesnut CH, Ettinger MP, Miller PD, et.al. Ibandronate produces significant antifracture efficacy in North American and European women: new clinical finding from BONE Curr Med Res Opin 2005;21:391-401.
  14. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis. The Prevent Recurrence of Osteoporosis Fractures (PROOF) study. Am J Med 2000;109:267-76.
  15. Cheung AM, Feid DS, Kapral M, et al. Prevention of osteoporosis and osteoporosis fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ 2004;170:1503-13.
  16. Cummings SR, San Martin J, McClung MR , et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361(8):756-65.
  17. O'Donnel S, CranneyA, Wells GA, et al. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Systematic Review 2006(4):CD005326,
  18. Ettinger B. Black D, Miltak, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 1999;282:637-45.
  19. Fleisch H. Bisphosphonates in bone diseases: from the laboratory to the patient. Academic Press. 2000. San Diego. 212 pp.
  20. Haopis ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a metaanalysis of phase III studies. Curr Med Res Opin 2008;24:237-45.
  21. Kanis JA, Burlet N, Coope C, et al on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int, 2008, Vol. 19, pp. 399-428
  22. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68.
  23. Neer RM, Chesnut CH, Silverman S, et al. Effect of Parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
  24. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-10.
  25. Recker RR, Marin F, Ish-Shalom S, et al. Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Mineral Res 2009;24:1358-68.
  26. Reginster JY, Seeman E, De Vernejoul MC, et.al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22.
  27. Richy F, Ethgen O, Bruyere O, et al. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004;15:301-10.
  28. Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59.
  29. Saag КD, Schnitzer TJ, Brown JP, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-9.
  30. Stoch SA, Zajic S, Stone J, et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. J Clin Pharmacol Ther 2009;86(2):175-82.
  31. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2522&mid=1085056570&magid=187

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies